Press Releases


ScinoPharm Reports Financial Performance for 2017

ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2017. The consolidated revenue was NT$3.516 billion (US$120 million), after-tax net profits were NT$ 422 million (US$14.4 million). The after-tax earnings per share was NT$0.53 (US$0.018).